Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.5527
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.1065
- MktCap 144109375042.0
- FreeCF/Share 1.8252
- PFCF 13.8887
- PE 14.6718
- Debt/Assets 0.2957
- DivYield 0.0679
- ROE 0.1091
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PFE | UBS | -- | Neutral | -- | $25 | Jan. 7, 2026 |
| Resumed | PFE | Citigroup | -- | Neutral | -- | $26 | Dec. 2, 2025 |
| Initiation | PFE | Scotiabank | -- | Sector Outperform | -- | $30 | Nov. 13, 2025 |
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
These 3 Stocks Trade at Discounts the Market Won't Ignore Forever
Published: January 05, 2026 by: MarketBeat
Sentiment: Positive
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is still the strongest market trend entering 2026, and the usual suspects like NVIDIA Corp. NASDAQ: NVDA and Alphabet Inc. NASDAQ: GOOGL are up once again on the first day of trading.
Read More
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Published: January 05, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
Read More
Pfizer 2026: The Reset Year
Published: January 02, 2026 by: Seeking Alpha
Sentiment: Negative
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D spending of $10.5–$11.5 billion.
Read More
Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
Ares Capital offers an especially juicy dividend. Energy Transfer has an impressive track record of increasing its distribution each quarter.
Read More
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
Published: December 31, 2025 by: MarketBeat
Sentiment: Negative
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold.
Read More
3 ultra-high-yield stocks to consider for $300 of dividend income in 2026
Published: December 31, 2025 by: Invezz
Sentiment: Positive
Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully vetted ultra-high-yield securities, each offering yields exceeding 6%, can reasonably generate approximately $300 in annual dividend income.
Read More
Jim Cramer Names His Favorite Dividend Stocks
Published: December 29, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jim Cramer has built a strong reputation in the industry. He's the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
3 Under-The-Radar Dividend Stocks to Buy on the Cheap
Published: December 24, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Dividend stocks have been under pressure in the past few years due to the broader economy's unpredictable swings.
Read More
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.
Read More
Pfizer says patient dies after receiving hemophilia drug in trial
Published: December 23, 2025 by: Reuters
Sentiment: Negative
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
Read More
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Read More
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III studies and commercializing new assets, but near-term valuation upside is unlikely until clearer growth visibility emerges.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Pfizer Stock Can Sink More. Here Is How
Published: December 17, 2025 by: Forbes
Sentiment: Negative
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Read More
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
Read More
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Read More
Pfizer shares fall after it forecasts 2026 revenue below estimates
Published: December 16, 2025 by: Proactive Investors
Sentiment: Negative
Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.
Read More
Pfizer's modest 2026 outlook shows its big investments will take time to pay off
Published: December 16, 2025 by: CNBC
Sentiment: Negative
Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion.
Read More
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Pfizer Declares First-Quarter 2026 Dividend
Published: December 12, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to brin.
Read More
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
Published: December 10, 2025 by: Reuters
Sentiment: Negative
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
Read More
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
Published: December 09, 2025 by: CNBC
Sentiment: Positive
Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharma's oral drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk's blockbuster weight loss injection Wegovy, but the pill is still in early-stage development.
Read More
Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons
Published: December 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
In the rushed emergency use approval of Covid vaccines, deaths were undisclosed. Thousands received shots before warnings of heart damage were released.
Read More
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains
Published: December 09, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved guidance, targeting $61–$64 billion in 2025 revenue and $3–$3.15 adjusted EPS, while managing leverage post-acquisitions. Patent expirations threaten $17–$18 billion in annual revenue by 2026–2028, but aggressive acquisitions, R&D investments and cost savings aim to offset losses and drive long-term growth.
Read More
Pfizer: The Market Is Still Wrong About It
Published: December 05, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with revenue and EPS down year-over-year, yet both beat estimates as Vyndaqel, Nurtec, and Padcev collectively offset fading COVID contributions. Pfizer's adjusted margin stayed near seventy‑six percent, and OPEX fell, while a $1.5 billion manufacturing optimization program should expand margins and earnings by 2027.
Read More
Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Read More
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000